Higher valent Pneumococcal Conjugate Vaccines: is it a roller coaster?

Godwin Oligbu; Godwin Oligbu

doi:10.3934/publichealth.2020004

AIMS Public Health

2020, Volume 7, Issue 1: 29-32. doi: 10.3934/publichealth.2020004

Previous Article Next Article

Editorial

Higher valent Pneumococcal Conjugate Vaccines: is it a roller coaster?

Godwin Oligbu ^,

Paediatric Infectious Diseases Research Group, St. George's University of London, Cranmer Terrace, London SW17 0RE, UK

Received: 15 December 2019 Accepted: 13 January 2020 Published: 17 January 2020

Citation: Godwin Oligbu. Higher valent Pneumococcal Conjugate Vaccines: is it a roller coaster?[J]. AIMS Public Health, 2020, 7(1): 29-32. doi: 10.3934/publichealth.2020004

Related Papers:

References

[1]	Kelly DF, Pollard AJ, Moxon ER (2005) Immunological memory: the role of B cells in long-term protection against invasive bacterial pathogens. JAMA 294: 3019-3023. doi: 10.1001/jama.294.23.3019
[2]	Avery OT, Dubos R (1931) The protective action of a specific enzyme against type III pneumococcus infections in mice. J Exp Med 54: 73-89. doi: 10.1084/jem.54.1.73
[3]	Schlesinger Y, Granoff DM, Murphy TV, et al. (1992) Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. JAMA 267: 1489-1494. doi: 10.1001/jama.1992.03480110065035
[4]	McVernon J, Mitchison NA, Moxon ER (2004) T helper cells and efficacy of Haemophilus influenzae type b conjugate vaccination. Lancet Infect Dis 4: 40-43. doi: 10.1016/S1473-3099(03)00859-4
[5]	Robbins JB, Austrian R, Lee CJ, et al. (1983) Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 148: 1136-1159. doi: 10.1093/infdis/148.6.1136
[6]	Jacobs M (2008) “Antimicrobial-resistant Streptococcus pneumoniae: Trends and management.”. Expert Rev Anti Infect Ther 6: 619-635. doi: 10.1586/14787210.6.5.619
[7]	Yildirim I, Stevenson A, Hsu KK, et al. (2012) Evolving picture of invasive pneumococcal disease in Massachusetts children: a comparison of disease in 2007–2009 with earlier periods. Pediatr Infect Dis J 31: 1016-1021.
[8]	Waight PA, Andrews NJ, Ladhani SN, et al. (2015) Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: An observational cohort study. Lancet Infect Dis 15: 535-543. doi: 10.1016/S1473-3099(15)70044-7
[9]	Conklin L, Loo JD, Kirk J, et al. (2014) Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children. Pediatr Infect Dis J 33: S109-S118. doi: 10.1097/INF.0000000000000078
[10]	O'Brien KL, Wolfson LJ, Watt JP, et al. (2009) Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374: 893-902. doi: 10.1016/S0140-6736(09)61204-6
[11]	Ladhani SN, Collins S, Djennad A, et al. (2018) Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. Lancet Infect Dis 18: 441-451. doi: 10.1016/S1473-3099(18)30052-5
[12]	European Centre for Disease Prevention and ControlInvasive pneumococcal disease. Stockholm: . Available from: https://ecdc.europa.eu/en/publication-data/invasive-pneumococcal-disease-annual-epidemiological-report-2017.
[13]	Greenberg D, Hoover PA, Vesikari T, et al. (2018) Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Vaccine 36: 6883-6891. doi: 10.1016/j.vaccine.2018.02.113
[14]	McFetridge R, Sobanjo-ter Meulen A, Folkerth SD, et al. (2018) Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 33: 2793-2799. doi: 10.1016/j.vaccine.2015.04.025
[15]	Makwana A, Sheppard C, Borrow R, et al. (2018) Characteristics of Children With Invasive Pneumococcal Disease After the Introduction of the 13-valent Pneumococcal Conjugate Vaccine in England and Wales, 2010–2016. Pediatr Infect Dis J 37: 697-703. doi: 10.1097/INF.0000000000001845
[16]	Oligbu G, Collins S, Sheppard C, et al. (2018) Risk of Invasive Pneumococcal Disease in Children with Sickle Cell Disease in England: A National Observational Cohort Study, 2010–2015. Arch Dis Child 103: 643-647.
[17]	Oligbu G, Fallaha M, Pay LLS (2019) Risk of invasive pneumococcal disease in children with sickle cell disease in the era of conjugate vaccines: a systematic review of the literature. Br J Haematol 185: 743-751. doi: 10.1111/bjh.15846
[18]	Thompson A, Lamberth E, Severs J, et al. (2019) Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 37: 6201-6207. doi: 10.1016/j.vaccine.2019.08.048
[19]	Ladhani SN, Ramsay ME (2015) Editorial commentary: the story of Sisyphus: why we need a universal pneumococcal vaccine to replace current conjugate vaccines. Clin Infect Dis 776-778. doi: 10.1093/cid/civ371

Reader Comments

Your name:*

Email:*
© 2020 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)